Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

OTHER 4NIH 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 3Lymphoid 3CNS 2Thoracic 1Genitourinary 1Gastrointestinal 1Dermatologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 278Lung Neoplasms 257Small Cell Lung Carcinoma 82Breast Neoplasms 59Mesothelioma, Malignant 49Adenocarcinoma of Lung 43Pancreatic Neoplasms 37Colonic Neoplasms 37Neoplasms 32Prostatic Neoplasms 30Ovarian Neoplasms 28Esophageal Neoplasms 26Neoplasm Metastasis 24Mesothelioma 24Melanoma 24Adenocarcinoma, Bronchiolo-Alveolar 24Stomach Neoplasms 22Colorectal Neoplasms 22Carcinoma, Renal Cell 22Rectal Neoplasms 20Urinary Bladder Neoplasms 18Uterine Cervical Neoplasms 17Squamous Cell Carcinoma of Head and Neck 17Carcinoma, Hepatocellular 17Brain Neoplasms 17Lymphoma, Non-Hodgkin 16Carcinoma, Ovarian Epithelial 16Thymoma 15Salivary Gland Neoplasms 15Lymphoma 15

Interventions

sapanisertib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Meningeal Neoplasms × Thoracic × Clear all
NCT04250545 2026-05-26

Testing of the Anti Cancer Drugs CB-839 HCl (Telaglenastat) and MLN0128 (Sapanisertib) in Advanced Stage Non-small Cell Lung Cancer

National Cancer Institute (NCI)

Phase 1 Active not recruiting
22 enrolled 14 charts
CNSThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Meningeal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡